<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910621</url>
  </required_header>
  <id_info>
    <org_study_id>AC-056C405</org_study_id>
    <nct_id>NCT03910621</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Miglustat in Chinese NPC Patients</brief_title>
  <official_title>A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV
      confirmatory study.

      Approximately 19 subjects with Niemann Pick Type C disease (NPC) will be enrolled in this
      study. The study will be conducted at 2 sites in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV
      confirmatory study.The study is conducted in Chinese subjects aged 4 years and older with
      Niemann Pick Type C disease (NPC). Approximately 19 subjects will be enrolled in this study.
      The study will be conducted at 2 sites in China. Patients will be treated with miglustat for
      12 months, efficacy and safety outcomes will be measured
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed change in HSEM (ms/deg)</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Change in HSEM from baseline to week 52</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pineda disability scale score</measure>
    <time_frame>baseline to week 52</time_frame>
    <description>Change in the modified Pineda disability scale score. The scale is assessing 4 key domains (manipulation, ambulation, language and swallowing). Individual scores of the domains are claculated ted into a composite score, 6 being the lowest and best score and 24 being the worst and highest score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent AEs and SAEs</measure>
    <time_frame>Baseline to 30 days after End of Treatment (Week 52)</time_frame>
    <description>Treatment-emergent adverse events (AEs) up to 30 days after EOT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Niemann-Pick Disease, Type C</condition>
  <arm_group>
    <arm_group_label>Miglustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Miglustat is administered three times a day as an oral capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miglustat</intervention_name>
    <description>capsule, oral use</description>
    <arm_group_label>Miglustat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed 2 pathogenic mutations in either Niemann Pick Type C Gene 1 or
             2 (NPC 1 or NPC 2) or 1 pathogenic mutation in either NPC1 or NPC2 plus a positive
             biomarker (oxysterol or lysosphingolipids or bile acids) plus high clinical suspicion

          -  Signed informed consent prior to any study-mandated procedure.

          -  For subjects who are younger than 18 years consent must be sought of at least one
             legal guardian who shall sign the informed consent form and indicate the relationship
             between him/her and the subject.

          -  Subjects who are 18 years or older must sign the consent. If the subject cannot make
             an independent decision to participate in the study, consent must be sought of the
             legal agents who shall sign the informed consent form and indicate the relationship
             between him/her and the subject.

          -  Male and female subjects aged 4 years and older.

          -  Subjects who can performed the tests for the horizontal and vertical saccadic eye
             movements;

          -  Subjects who are able to swallow the study drug;

          -  Women of childbearing potential are only eligible if the following applies:

          -  Negative urine pregnancy test at screening.

          -  Agreement to undertake monthly urine pregnancy tests during the study and up to at
             least 30 days after study treatment discontinuation.

          -  Agreement to use one of the methods of birth control / follow the contraception scheme
             from screening up to at least 30 days after study treatment discontinuation.

          -  A fertile male (physiologically capable of fathering a child according to
             investigator's judgment) is eligible only if he agrees to use a condom during the
             treatment period and for an additional 12 weeks after treatment discontinuation.

        Exclusion Criteria:

        Subjects must not fulfill any of the following exclusion criteria. It is not permitted to
        waive any of the criteria for any subject:

          -  Subjects suffering from clinically significant diarrhea (&gt;3 liquid stools per day for
             &gt;7 days) without definable cause within 3 months before enrollment.

          -  Known hypersensitivity to the investigational treatment or drugs of the same class, or
             any of their excipients.

          -  Subjects who suffer from renal insufficiency with a creatinine clearance rate (CCR) of
             &lt; 30ml/min per 1.73m2.

          -  Pregnant, planning to be become pregnant or lactating females, not using reliable
             birth control male adult subjects.

          -  Previous exposure to investigational treatment for more than 12 months before study
             start.

          -  Planned or current treatment with another investigational treatment up to 3 months
             prior to randomization. Symptomatic therapies are allowed (such as curcumin).

          -  Any known factor or disease that might interfere with treatment compliance, study
             conduct, or interpretation of the results, such as drug or alcohol dependence or
             psychiatric disease, end stage disease including wheelchair bound patients, bedridden
             patients etc.

          -  Subjects who are judged unqualified for the clinical trial by the investigator.

          -  Subjects who suffer lysosomal storage diseases, enzyme deficiency or neurological
             diseases other than NPC.

          -  Subjects who suffer variant filipin staining without confirmatory genetic diagnosis of
             NPC.

          -  Subjects with uncontrolled epilepsy.

          -  Subjects with complete ophthalmoplegia.

          -  Known concomitant life-threatening disease with a life expectancy &lt; 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yue Wu</last_name>
    <role>Study Director</role>
    <affiliation>Janssen China R&amp;D</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University first Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

